Skip to main content
Erschienen in: Neurological Sciences 9/2023

03.04.2023 | Original Article

Patient characteristics and outcome in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis

verfasst von: Jingfang Lin, Jierui Wang, Jinmei Li

Erschienen in: Neurological Sciences | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis is a rare subtype of autoimmune encephalitis. We report patients diagnosed with anti-AMPAR encephalitis in western China, focusing on their clinical presentations, imaging results, treatment strategies, and prognosis.

Methods

Data from patients diagnosed with anti-AMPAR encephalitis in the neurology center of West China Hospital from August 2018 to July 2021 were retrospectively collected and analyzed. Based on the diagnostic criteria of autoimmune encephalitis, nine cases were included.

Results

Four patients (44%) were males, and the median age at presentation was 54 years (range, 25–85). Short-term memory loss was the most common initial symptom. Additional types of autoantibodies were identified in three patients. After presentation, four patients were found to have tumors: two with small cell lung cancer, one with ovarian teratoma, and one with thymoma. All patients accepted first-line immune therapy, and follow-up was available from 8 patients (median 20 weeks, range 4–78). At the last follow-up, three patients showed good outcomes (modified Rankin scale [mRS] 0–2; 37.5%). Five patients showed poor outcomes (mRS 3–6; 62.5%): two had minimal changes and remained hospitalized, two had residual severe cognitive impairments, and one patient died during follow-up. Outcomes were worse among patients with tumors. Finally, only one patient experienced relapse during follow-up.

Conclusion

Anti-AMPAR encephalitis should be considered in the differential diagnosis for middle- and senior-aged patients who present with predominantly acute or subacute short-term memory impairment. The long-term prognosis is correlated with the presence of a tumor.
Literatur
1.
2.
Zurück zum Zitat Bataller L, Galiano R, Garcia-Escrig M et al (2010) Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74:265–267CrossRefPubMedPubMedCentral Bataller L, Galiano R, Garcia-Escrig M et al (2010) Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74:265–267CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Graus F, Boronat A, Xifro X et al (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859CrossRefPubMed Graus F, Boronat A, Xifro X et al (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859CrossRefPubMed
4.
Zurück zum Zitat Wei YC, Liu CH, Lin JJ et al (2013) Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 261:129–133CrossRefPubMed Wei YC, Liu CH, Lin JJ et al (2013) Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 261:129–133CrossRefPubMed
5.
Zurück zum Zitat Joubert B, Kerschen P, Zekeridou A et al (2015) Clinical spectrum of encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 72:1163–1169CrossRefPubMed Joubert B, Kerschen P, Zekeridou A et al (2015) Clinical spectrum of encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 72:1163–1169CrossRefPubMed
6.
Zurück zum Zitat Hoftberger R, van Sonderen A, Leypoldt F et al (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 84:2403–2412CrossRefPubMedPubMedCentral Hoftberger R, van Sonderen A, Leypoldt F et al (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 84:2403–2412CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165CrossRefPubMedPubMedCentral Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Mahajan S, Appleby BS (2017) Comprehensive and methodical: diagnostic and management approaches to rapidly progressive dementia. Curr Treat Options Neurol 19:40CrossRefPubMed Mahajan S, Appleby BS (2017) Comprehensive and methodical: diagnostic and management approaches to rapidly progressive dementia. Curr Treat Options Neurol 19:40CrossRefPubMed
9.
Zurück zum Zitat Day GS, Yarbrough MY, Kortvelyessy P et al (2021) Prospective quantification of CSF biomarkers in antibody-mediated encephalitis. Neurology 96:e2546–e2557CrossRefPubMedPubMedCentral Day GS, Yarbrough MY, Kortvelyessy P et al (2021) Prospective quantification of CSF biomarkers in antibody-mediated encephalitis. Neurology 96:e2546–e2557CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Haselmann H, Mannara F, Werner C et al (2018) Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron 100(91–105):e109 Haselmann H, Mannara F, Werner C et al (2018) Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron 100(91–105):e109
11.
Zurück zum Zitat Traynelis SF, Wollmuth LP, McBain CJ et al (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496CrossRefPubMedPubMedCentral Traynelis SF, Wollmuth LP, McBain CJ et al (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Sprengel R (2006) Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 326:447–455CrossRefPubMed Sprengel R (2006) Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 326:447–455CrossRefPubMed
13.
Zurück zum Zitat Peng X, Hughes EG, Moscato EH et al (2015) Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 77:381–398CrossRefPubMedPubMedCentral Peng X, Hughes EG, Moscato EH et al (2015) Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 77:381–398CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Zhang TY, Cai MT, Zheng Y et al (2021) Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis: a review. Front Immunol 12:652820CrossRefPubMedPubMedCentral Zhang TY, Cai MT, Zheng Y et al (2021) Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis: a review. Front Immunol 12:652820CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Finke C, Kopp UA, Pruss H et al (2012) Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 83:195–198CrossRefPubMed Finke C, Kopp UA, Pruss H et al (2012) Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 83:195–198CrossRefPubMed
16.
Zurück zum Zitat Arino H, Armangue T, Petit-Pedrol M et al (2016) Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 87:759–765CrossRefPubMedPubMedCentral Arino H, Armangue T, Petit-Pedrol M et al (2016) Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 87:759–765CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lin J, Li C, Li A et al (2021) Long-term cognitive and neuropsychiatric outcomes of anti-GABABR encephalitis patients: a prospective study. J Neuroimmunol 351:577471CrossRefPubMed Lin J, Li C, Li A et al (2021) Long-term cognitive and neuropsychiatric outcomes of anti-GABABR encephalitis patients: a prospective study. J Neuroimmunol 351:577471CrossRefPubMed
Metadaten
Titel
Patient characteristics and outcome in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis
verfasst von
Jingfang Lin
Jierui Wang
Jinmei Li
Publikationsdatum
03.04.2023
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 9/2023
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-023-06769-x

Weitere Artikel der Ausgabe 9/2023

Neurological Sciences 9/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.